- Home
- FBRX vs SOR Comparison
FBRX vs SOR Comparison
Compare FBRX & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$28.31
Company Overview
Basic Information| Metric | FBRX | SOR |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 391.5M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FBRX | SOR |
|---|---|---|
| Price | $28.31 | $47.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 180.3K | 12.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.91 | $38.66 |
| 52 Week High | $35.62 | $50.41 |
Technical Indicators
Market Signals| Indicator | FBRX | SOR |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 45.72 |
| Support Level | $26.67 | $47.45 |
| Resistance Level | $32.12 | $50.05 |
| Average True Range (ATR) | 2.39 | 1.08 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 30.31 | 41.47 |
Price Performance
Historical Comparison FBRX
SOR
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.